Remap Consulting

𝐖𝐞'𝐫𝐞 𝐦𝐨𝐯𝐢𝐧𝐠 𝐦𝐨𝐫𝐞 𝐟𝐨𝐫 𝐨𝐮𝐫 𝐦𝐞𝐧𝐭𝐚𝐥 𝐡𝐞𝐚𝐥𝐭𝐡 🏃♀️ As you may know, Remap proudly supports two local charities each year, and for 2024, we're fundraising for Manchester Mind. Manchester Mind partnered with the Mental Health Foundation to embrace the theme "Movement: Moving More for Our Mental Health" during #MentalHealthAwarenessWeek in May. Inspired by this, we decided to make movement a year-round commitment 🗓 Over the past month, we've been motivating our team to stay active through a physical challenge, boosting our fundraising efforts. In honour of Remap’s 10th anniversary, we’ve set an ambitious goal: to collectively travel the distance from our UK office in Alderley Park to our office in Switzerland! This challenge not only symbolises our journey and growth as a company but also promotes a healthy lifestyle. To achieve this, each team member needs to move an average of 2.5km daily, perfectly aligning with NHS physical activity guidelines. 𝐃𝐢𝐝 𝐲𝐨𝐮 𝐤𝐧𝐨𝐰 𝐭𝐡𝐚𝐭 𝐫𝐞𝐠𝐮𝐥𝐚𝐫 𝐩𝐡𝐲𝐬𝐢𝐜𝐚𝐥 𝐚𝐜𝐭𝐢𝐯𝐢𝐭𝐲 𝐡𝐚𝐬 𝐛𝐞𝐞𝐧 𝐬𝐡𝐨𝐰𝐧 𝐭𝐨: 😁 Boost mood - exercise induces chemical changes in the brain that elevate mood 💪 Enhance self-esteem 🌊 Reduces anxiety and stress Let’s move more, feel better, and support a great cause together. Let’s move more, feel better, and support a great cause together. 💰 To donate, please click here:  👉 https://lnkd.in/eVSYcc2U #movingformentalhealth #marketaccess #healthcare #mentalhealthawareness #fundraising #workplacewednesday #workplaceinitiative #csr

𝐌𝐈𝐃𝐃𝐋𝐄 𝐄𝐀𝐒𝐓 𝐋𝐀𝐓𝐄𝐒𝐓: 🇸🇦 The Saudi Food & Drug Authority (SFDA) has released new Economic Evaluation Studies (EES) Guidelines to support manufacturers and marketing authorisation holders in evaluating the cost-effectiveness of healthcare interventions. These studies will help the SFDA assess the value of new treatments against existing healthcare practices in Saudi Arabia, promoting more informed decision-making in the healthcare sector. Analyst Manahill Baig has summarised how these guidelines reflect Saudi Arabia’s commitment to advancing its healthcare industry and positioning the country as an emerging leader in the global biopharma market in our latest article: ➡️ 🔗 https://lnkd.in/eM6cKGaH #middleeastnews #marketaccess #healthcare #pharmaceuticals #emergingmarkets #sfda

The Joint Nordic HTA bodies have released draft process guidelines aimed at streamlining joint clinical assessments (JCAs) for new medicinal products. This initiative aligns with the European Medicines Agency’s scientific advice process, enhancing collaboration and efficiency across the Nordic countries. Key areas include managing outcomes, addressing multiplicity issues, and integrating real-world evidence. 🌍 For more detailed insights, check out the full article here 👉 https://lnkd.in/eUASi8Mc #HTA #Pharma #HealthTechnologyAssessment #ClinicalAssessments #MarketAccess #Healthcare #JointClinicalAssessment

The recently released pharmaceutical expenditure report from AIFA reveals critical insights into Italy's national and regional pharmaceutical expenditure for 2023: 💰 𝐍𝐞𝐭 𝐞𝐱𝐩𝐞𝐧𝐝𝐢𝐭𝐮𝐫𝐞: €7.7 billion, a slight increase from last year 📈 𝐃𝐢𝐫𝐞𝐜𝐭 𝐩𝐮𝐫𝐜𝐡𝐚𝐬𝐞𝐬: Exceeded the cap by €3.36 billion #️⃣ 𝐂𝐨𝐧𝐯𝐞𝐧𝐭𝐢𝐨𝐧𝐚𝐥 𝐬𝐩𝐞𝐧𝐝𝐢𝐧𝐠: Stayed within the cap, generating a surplus of €832.9 million 🔬 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬: Aligned with the government's fund at €770.2 million 💸 𝐏𝐚𝐲𝐛𝐚𝐜𝐤 𝐜𝐨𝐧𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧𝐬: Pharmaceutical companies contributed €424.2 million Despite efforts to control costs, Italy faces challenges in balancing healthcare needs and budget constraints. Explore now: https://lnkd.in/gyfmz5nh #Pharmaceuticals #Healthcare #AIFA #MarketAccess #PharmaTrends #HealthcareBudget #InnovativeMedicines #ItalyHealthcare #PharmaceuticalSpending

Last week, the French National Authority for Health (HAS) released its annual report, highlighting a ground-breaking new doctrine from the Transparency Commission. This doctrine aims to accelerate the development of new medications, particularly for #rarediseases and #oncology, by allowing non-comparative studies and conditional market authorisations (AMM). It seeks to balance rapid clinical development with managing uncertainties to benefit patients. This shift could significantly impact how new drugs reach the market. 𝐒𝐨 𝐰𝐡𝐚𝐭 𝐝𝐨𝐞𝐬 𝐭𝐡𝐢𝐬 𝐦𝐞𝐚𝐧? 💨 𝐅𝐚𝐬𝐭𝐞𝐫 𝐦𝐚𝐫𝐤𝐞𝐭 𝐚𝐜𝐜𝐞𝐬𝐬: This new approach allows for quicker introduction of innovative treatments, particularly in areas with urgent needs such as rare diseases and oncology 🎯 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐚𝐝𝐚𝐩𝐭𝐚𝐭𝐢𝐨𝐧: Manufacturers must now focus on providing robust methodological plans and justifying indirect comparison data to meet the new requirements, including high-quality indirect evidence and pre-planned external comparators Explore more insights here 🔗 https://lnkd.in/ee7u5_gQ #Pharmaceuticals #DrugDevelopment #MarketAccess #HAS #PatientAccess #Healthcare #Innovativetreatments * 𝒘𝒓𝒊𝒕𝒕𝒆𝒏 𝒃𝒚 Solen Monteil

🚨 𝐇𝐚𝐯𝐞 𝐲𝐨𝐮 𝐡𝐞𝐚𝐫𝐝? Germany's new Medicines Research Act introduces confidential rebates for pharmaceutical companies, aiming to enhance market attractiveness. However, recent amendments impose significant restrictions, including a mandatory 9% discount and limited eligibility to those conducting research in Germany. Doctors will have access to rebate information to ensure cost-effective prescriptions. The provision is set until 30 June 2028, with an impact evaluation by the Ministry of Health due by the end of 2026. Read more here 👉 https://lnkd.in/e6kNbQNC #MarketAccess #Pharmaceuticals #Healthcare #ConfidentialRebates #MedicinesResearchAct #HealthcarePolicy * 𝒘𝒓𝒊𝒕𝒕𝒆𝒏 𝒃𝒚 Giulia Chirico

In a ground-breaking development for the pharmaceutical industry and patients with haemophilia B, Hemgenix (etranacogene dezaparvovec) has become the first treatment to enter NHS England’s Innovative Medicines Fund (IMF) with managed access. ⚕️ This arrangement allows patients to receive promising treatments that might not be recommended otherwise due to uncertain clinical or cost-effectiveness evidence. This milestone follows a commercial agreement between NHS England and manufacturer CSL Behring. Hemgenix is a gene therapy that involves a one-time infusion lasting approximately 1-2 hours, offering a potentially curative treatment for haemophilia B. This therapy represents a significant advancement in managing this genetic disorder by reducing the frequency of bleeding episodes and decreasing the need for regular infusions of clotting factors, which are typically administered once or twice a week for severe cases. 🩸 The #InnovativeMedicinesFund is designed to fast-track promising treatments addressing unmet clinical needs, providing patients quicker access while data on their efficacy and safety is gathered. An estimated 2,000 people in the UK have haemophilia B, and about 250 of them will be eligible for this new treatment. Hemgenix’s inclusion in this fund marks a major step forward in adopting advanced therapies within the NHS framework, offering hope for individuals with rare and severe medical conditions. 🧬 🗣 Professor Sir Stephen Powis, NHS National Medical Director, commented, “It is a one-time therapy that could be truly life-changing for some, as it could help people avoid the need for regular hospital visits.” Discover more insights here ➡ https://lnkd.in/ee7u5_gQ #marketaccess #patientaccess #imf #therapies #nhsengland #pharma #healthcare #haemophilia * 𝒘𝒓𝒊𝒕𝒕𝒆𝒏 𝒃𝒚 Rahul V.

At the recent German Network for Personalised Medicine (DNPM) congress, Josef Hecken, chairman of the Federal Joint Committee (G-BA), shared key shared innovative approaches to evidence generation and patient care, signalling a shift from traditional drug trials. This could mean easier access to personalised therapies, benefiting both patients and manufacturers. 🏥 Dive into the details and implications of this transformative change in our latest insider insight ➡ 🔗 https://lnkd.in/evj6naTn #MarketAccess #PatientAccess #PersonalisedMedicine #HealthcareInnovation #DrugTrials #Pharma #Biotech #PatientCare * 𝒘𝒓𝒊𝒕𝒕𝒆𝒏 𝒃𝒚 Manahill Baig

Let's recap this year's Health Technology Assessment international (HTAi) annual meeting 🚀 We are thrilled to share the full summary of #HTAi2024Seville which covers key discussions and insights on the future of Health Technology Assessment (HTA). 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: 🧑 The transition from HTA gatekeepers to sustainable system shapers 🌿 Integrating environmental sustainability into HTA processes 🤖 The role of AI in enhancing HTA efficiency 🧬 The impact of tumour-agnostic approvals in oncology 🌍 Global initiatives to improve HTA consistency across countries Download now: https://lnkd.in/ejpdu5Qj Have any questions or would like to discuss HTA in further detail? Reach out to Charles Hewitt! #HTA #healthtechnologyassessment #marketaccess #healthcare #pharma #oncology #aiinhealthcare

📢 The European Commission has released the draft for the third Implementation Act (IA) under the EU Health Technology Assessment (HTA). This draft outlines procedural rules for the cooperation between the Member State Coordination Group on HTA, the European Medicines Agency (EMA), and other relevant expert panels. 𝐊𝐞𝐲 𝐡𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: ‣ Coordination and information exchange between the HTA Secretariat and EMA ‣ Establishing consistency and timelines for joint clinical assessments and scientific consultations ‣ Clear guidelines for the identification and involvement of expert panels and individual experts ‣ Robust measures for protecting confidential information throughout the process The IA ensures a streamlined, transparent, and secure evaluation process for medicinal products and medical devices across the EU, facilitating better healthcare outcomes. 📅 The consultation period is open until July 24th. Read more and participate here: 🔗 https://lnkd.in/gmAnkey4 ✅ Please reach out to Kate Noble to understand the implications of this update and how we can assist you in navigating these changes. #EUHTA #HTAregulation #jointclinicalassessment #jca #healthcare #marketaccess #regulationchanges